After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized by both increasing volumes and an increased focus on costs.
In 2024, we have taken clear steps both towards realizing our vision of contributing to more patients having access to adequate treatments, and towards becoming a company with steadily increasing sales. Thanks to the fact that we have successfully produced significantly larger volumes of silica than before, sales of our main product NLAB Saga® have started. In addition, we have sold our first non-silica-based purification media (NLAB® Siv), carried out a first comprehensive application development project on behalf of a customer, and developed another purification media (NLAB® Idun) that we will launch in 2025.
In China, we have achieved commercial advances during the year. At the beginning of the year, we set up our own dedicated team that sells NLAB Saga®, i.e. silica for preparative chromatography, directly to end customers in China after we renegotiated the agreement with our distributor. This has been very beneficial for us and the intensive work the team has done is now starting to pay off. Our main customer is a pharmaceutical manufacturer that uses NLAB Saga® in the production of several different GLP-1 analogues. They have repeatedly placed orders, which is a clear confirmation that our product meets their needs and is competitive. This also means that NLAB Saga® is now used for the manufacturing of pharmaceuticals on an industrial scale. Our own conviction in the performance of our products has thus been translated into improved production economics for our customers.
Our view of the market in China has become increasingly positive during the year. In 2025, China will be a priority market for us where we will continue to work closely with our largest customer, and at the same time develop similar customers from using our product at lab scale to using it in large-scale production.
Our second major focus area in 2025 is to optimize the silica production process. In 2024, several improvements have been initiated, and production has become more stable. In 2025, we devote further resources to intensify this work and implement several projects with the view of increasing both production efficiency and product yield, and to further stabilize the process. This work is vital as it lays the foundation for future sales growth and thus profitability.
One of our biggest challenges is time; Partly that things take longer than we would like, and partly that it is difficult to assess when in time customers will place orders. The rights issues we carried out in 2024 made us less sensitive to these time aspects and created better conditions for us to methodically build up our sales. The rights issues also provided us with working capital to continue the silica production, and strengthened our financial position so that we can win customers’ trust as a long-term supplier. In this context, I would like to extend a big thank you to our shareholders for your patience and continued trust.
I would also like to thank my employees who impressively take on the challenges we face and whose efforts have taken the company to where we are today. In 2024, we have taken the first real steps towards establishing ourselves as a recognized provider of high-quality products and services in preparative chromatography. We have proven our product quality, and we see strong market growth globally in our segment. We have also streamlined the company, which means that we can focus our work and optimize our resources.
All in all, we have never been in a better position than now to get meaningful sales of both purification products and application services going. We thus enter 2025 with high hopes for continued sales growth. I look forward to leading the company further towards our goal of building a profitable business.
Södertälje in March 2025
Andreas Bhagwani, CEO
CEO Comment Annual Report 2024
After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized by both increasing volumes and an increased focus on costs.
In 2024, we have taken clear steps both towards realizing our vision of contributing to more patients having access to adequate treatments, and towards becoming a company with steadily increasing sales. Thanks to the fact that we have successfully produced significantly larger volumes of silica than before, sales of our main product NLAB Saga® have started. In addition, we have sold our first non-silica-based purification media (NLAB® Siv), carried out a first comprehensive application development project on behalf of a customer, and developed another purification media (NLAB® Idun) that we will launch in 2025.
In China, we have achieved commercial advances during the year. At the beginning of the year, we set up our own dedicated team that sells NLAB Saga®, i.e. silica for preparative chromatography, directly to end customers in China after we renegotiated the agreement with our distributor. This has been very beneficial for us and the intensive work the team has done is now starting to pay off. Our main customer is a pharmaceutical manufacturer that uses NLAB Saga® in the production of several different GLP-1 analogues. They have repeatedly placed orders, which is a clear confirmation that our product meets their needs and is competitive. This also means that NLAB Saga® is now used for the manufacturing of pharmaceuticals on an industrial scale. Our own conviction in the performance of our products has thus been translated into improved production economics for our customers.
Our view of the market in China has become increasingly positive during the year. In 2025, China will be a priority market for us where we will continue to work closely with our largest customer, and at the same time develop similar customers from using our product at lab scale to using it in large-scale production.
Our second major focus area in 2025 is to optimize the silica production process. In 2024, several improvements have been initiated, and production has become more stable. In 2025, we devote further resources to intensify this work and implement several projects with the view of increasing both production efficiency and product yield, and to further stabilize the process. This work is vital as it lays the foundation for future sales growth and thus profitability.
One of our biggest challenges is time; Partly that things take longer than we would like, and partly that it is difficult to assess when in time customers will place orders. The rights issues we carried out in 2024 made us less sensitive to these time aspects and created better conditions for us to methodically build up our sales. The rights issues also provided us with working capital to continue the silica production, and strengthened our financial position so that we can win customers’ trust as a long-term supplier. In this context, I would like to extend a big thank you to our shareholders for your patience and continued trust.
I would also like to thank my employees who impressively take on the challenges we face and whose efforts have taken the company to where we are today. In 2024, we have taken the first real steps towards establishing ourselves as a recognized provider of high-quality products and services in preparative chromatography. We have proven our product quality, and we see strong market growth globally in our segment. We have also streamlined the company, which means that we can focus our work and optimize our resources.
All in all, we have never been in a better position than now to get meaningful sales of both purification products and application services going. We thus enter 2025 with high hopes for continued sales growth. I look forward to leading the company further towards our goal of building a profitable business.
Södertälje in March 2025
Andreas Bhagwani, CEO
Share this: